Global /United States /Healthcare /Drug Manufacturers - Specialty & Generic /RVMD

Revolution Medicines, Inc.

RVMD

• NASDAQ: RVMD • Delayed

140.55USD -3%

As of 11 July 2026, Revolution Medicines, Inc. has a market cap of $29.56B USD, ranking #859 globally and #341 in the United States. It ranks #65 in the Healthcare sector, and #2 in the Drug Manufacturers - Specialty & Generic industry.

Global Rank

859

1d: -3

1w: -7

1m: -

Country Rank

341

1d: -1

1w: -1

1m: -

Sector Rank

1d: 0

1w: 0

1m: -

Industry Rank

1d: 0

1w: 0

1m: -

Key Stats

Market Cap

$29.56BUSD

Enterprise Value

$27.97BUSD

EBITDA (TTM)

-$1.17BUSD

Net Income (TTM)

-$1.13BUSD

PB Ratio

17.0

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mark Goldsmith open_in_new

Employees

883

Founded

2014

IPO

13 Feb 2020

Website

revmed.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3%	-0.7%	52%	44%	142%	76%	239%	498%	316%

News

RVMD Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	RVMD Revolution Medicines Inc Ordinary Shares ISIN: US76155X1000 Shares Out.: Shares Outstanding: 212.596M¹ Shares Float: 190.104M² TV: TradingView: NASDAQ: RVMD SA: Stock Analysis: NASDAQ: RVMD YF: Yahoo Finance: RVMD GF: Google Finance: NASDAQ: RVMD NQ: NASDAQ: RVMD BA: Barron's: RVMD MS: Morningstar: XNAS: RVMD	140.55 USD	TV: TradingView: NASDAQ: RVMD SA: Stock Analysis: NASDAQ: RVMD YF: Yahoo Finance: RVMD GF: Google Finance: NASDAQ: RVMD NQ: NASDAQ: RVMD BA: Barron's: RVMD MS: Morningstar: XNAS: RVMD
Borsa Italiana (MIL / BIT) MIC: XMIL	1RVMD Revolution Medicines Inc Ordinary Shares ISIN: US76155X1000 TV: TradingView: MIL: 1RVMD SA: Stock Analysis: BIT: 1RVMD YF: Yahoo Finance: 1RVMD.MI GF: Google Finance: BIT: 1RVMD BA: Barron's: 1RVMD MS: Morningstar: XMIL: 1RVMD	163.60 EUR	TV: TradingView: MIL: 1RVMD SA: Stock Analysis: BIT: 1RVMD YF: Yahoo Finance: 1RVMD.MI GF: Google Finance: BIT: 1RVMD BA: Barron's: 1RVMD MS: Morningstar: XMIL: 1RVMD
Deutsche Börse Xetra (XETRA) MIC: XETR	42Z Revolution Medicines Inc Ordinary Shares ISIN: US76155X1000 TV: TradingView: XETR: 42Z SA: Stock Analysis: ETR: 42Z YF: Yahoo Finance: 42Z.DE GF: Google Finance: FRA: 42Z BA: Barron's: 42Z MS: Morningstar: XETR: 42Z	163.75 EUR	TV: TradingView: XETR: 42Z SA: Stock Analysis: ETR: 42Z YF: Yahoo Finance: 42Z.DE GF: Google Finance: FRA: 42Z BA: Barron's: 42Z MS: Morningstar: XETR: 42Z
Frankfurt Stock Exchange (FRA) MIC: XFRA	42Z Revolution Medicines Inc Ordinary Shares ISIN: US76155X1000 TV: TradingView: FWB: 42Z SA: Stock Analysis: FRA: 42Z YF: Yahoo Finance: 42Z.F GF: Google Finance: FRA: 42Z BA: Barron's: 42Z MS: Morningstar: XFRA: 42Z	167.00 EUR	TV: TradingView: FWB: 42Z SA: Stock Analysis: FRA: 42Z YF: Yahoo Finance: 42Z.F GF: Google Finance: FRA: 42Z BA: Barron's: 42Z MS: Morningstar: XFRA: 42Z
Mexican Bolsa (BMV) MIC: XMEX	RVMD Revolution Medicines Inc Ordinary Shares ISIN: US76155X1000 TV: TradingView: BMV: RVMD SA: Stock Analysis: BMV: RVMD YF: Yahoo Finance: RVMD.MX GF: Google Finance: BMV: RVMD BA: Barron's: RVMD MS: Morningstar: XMEX: RVMD	2,664.22 MXN	TV: TradingView: BMV: RVMD SA: Stock Analysis: BMV: RVMD YF: Yahoo Finance: RVMD.MX GF: Google Finance: BMV: RVMD BA: Barron's: RVMD MS: Morningstar: XMEX: RVMD

Show all 5 markets

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Revolution Medicines, Inc.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (United States)

Name	Market Cap (USD) diff.	PE	Country
Indivior PLC LSE: INDV	$2.07B 1.54B GBP -93%	-	United States
BellRing Brands, Inc. NYSE: BRBR	$2.06B -93%	12.1	United States
Endo, Inc. OTCMKTS: NDOI	$1.8B -94%	0.4	United States
Dynavax Technologies Corp. NASDAQ: DVAX	$1.76B -94%	-	United States
ArriVent BioPharma, Inc. NASDAQ: AVBP	$1.33B -96%	-	United States
Nature's Sunshine Products, Inc. NASDAQ: NATR	$471.83M -98%	25.4	United States

Industry: Drug Manufacturers - Specialty & Generic (Global)

Name	Market Cap (USD) diff.	PE	Country
Teva Pharmaceutical Industries Ltd. TLV: TEVA	$36.12B 108.92B ILS 22%	24.2	Israel
Zhejiang NHU Company Ltd. SHE: 002001	$15.8B 107.34B CNY -47%	16.0	China
Cipla Ltd. NSE: CIPLA	$11.16B 1.06T INR -62%	23.4	India
Lupin Ltd. NSE: LUPIN	$11.04B 1.05T INR -63%	22.7	India
Haisco Pharmaceutical Group Co., Ltd. SHE: 002653	$9.07B 61.6B CNY -69%	80.6	China
ABIVAX Société Anonyme EPA: ABVX	$8.65B 7.57B EUR -71%	-	France

chevron_leftBack